Press Release: aaps silver coating patent receives notice of allowance by US Patent and Trademark office

aap Implantate AG / aaps silver coating patent receives notice of allowance by US Patent and Trademark office . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE) announced today that the United States Patent and Trademark Office (USPTO) has issued the notice of allowance for aaps silver coating patent.

This notice represents a significant advancement in aap's strategy to build a coherent trauma portfolio which addresses broad indications as well as unmet customers' needs. The fundamental nature of this technology lies in the property of silver as a coating material for medical devices to prevent biofilm formation and hence reduce infection risk. aap's silver coating as a platform technology can be applied not only to the existing trauma portfolio but also for other orthopedic implants. Such a technology which aims to reduce infection rates directly contributes to improved patient care and represents a major step in saving healthcare costs.

Bruke Seyoum Alemu, COO, comments: "We are excited about this advancement in the development of our silver coating technology which extends our IP protected trauma portfolio. Complementing our existing LOQTEQ(R) portfolio, silver-coated implants will strengthen aap's strategy to offer added-value trauma products addressing the growing infection care market. We expect to present the results of the first animal trials for local and systemic tolerability in the second quarter of 2014."

aap plans to submit the technology for regulatory approval within 12-15 months, which would allow first EU market introduction in 2015.

______________________________________________________

aap Implantate AG (ISIN DE0005066609)

- Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact:

aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: m.heydrich@aap.de

aap_Press Release 6.2.2014: http://hugin.info/130121/R/1759897/595421.pdf

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: aap Implantate AG via Globenewswire

HUG#1759897

--- End of Message ---

aap Implantate AG

Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

www.aap.de (END) Dow Jones Newswires

   February 06, 2014 10:57 ET (15:57 GMT)- - 10 57 AM EST 02-06-14